Trial of trefoil factor 3 enemas, in combination with oral 5-aminosalicylic acid, for the treatment of mild-to-moderate left-sided ulcerative colitis

Alimentary Pharmacology and Therapeutics

Volumn 21, Issue 11, 2005, Pages 1357-1364

  Mahmood, A ^a   Melley, L ^a   Fitzgerald, A J ^a   Ghosh, S ^a   Playford, R J ^a,b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ENEMA; MESALAZINE; PLACEBO; RECOMBINANT TREFOIL FACTOR FAMILY 3; SODIUM CHLORIDE; STEROID; TREFOIL PEPTIDE; UNCLASSIFIED DRUG;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; CHI SQUARE DISTRIBUTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HEMATOCHEZIA; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SCORING SYSTEM; SIDE EFFECT; TREATMENT OUTCOME; ULCERATIVE COLITIS; ULCERATIVE COLITIS DISEASE ACTIVITY INDEX;

ADMINISTRATION, ORAL; ADULT; COLITIS, ULCERATIVE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ENEMA; FEMALE; HUMANS; MALE; MESALAMINE; MIDDLE AGED; MUCINS; MUSCLE PROTEINS; PATIENT COMPLIANCE; PEPTIDES; TREATMENT OUTCOME;

EID: 20444450031     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2005.02436.x     Document Type: Article

References (34)

1. Hanauer SB. Medical therapy of ulcerative colitis. Lancet 1993; 342: 412-7.
2. Farrell RJ, Peppercorn MA. Ulcerative colitis. Lancet 2002; 359: 331-40.
3. Podolsky DK. Inflammatory bowel disease. NEJM 2002; 347: 417-29.
4. Thim L, Woldike HF, Nielsen PF. Characterisation of human and rat intestinal trefoil factor produced in yeast. Biochemistry 1995; 34: 4757-64.
5. Taupin D, Podolsky DK. Trefoil factors: initiators of mucosal healing. Nat Rev Mol Cell Biol 2003; 4: 721-32.
6. Dignass A, Lynch-Devaney K, Kindon H, et al. Trefoil peptides promote epithelial migration through a transforming growth factor-beta independent pathway. J Clin Invest 1994; 94: 376-83.
7. Mashimo H, Wu DC, Podolsky DK, et al. Impaired defense of intestinal mucosa in mice lacking intestinal trefoil factor. Science 1996; 274: 262-5.
8. Hauser F, Poulsom R, Chinery R, et al. hP1.B, a human p-domain peptide homologous with rat intestinal trefoil factor, is expressed also in the ulcer-associated cell lineage and the uterus. Proc Natl Acad Sci U S A 1993; 90: 6961-5.
9. Kanai M, Mullen C, Podolsky DK. Intestinal trefoil factor induces inactivation of extracellular signal-regulated protein kinase in intestinal epithelial cells. Proc Natl Acad Sci U S A 1998; 95: 178-82.
10. Jansen A, Paulsen FP, Varoga D, et al. Restitution of wounded cornea by TFF-peptides. Invest Ophthalmol Vis Sci 2004; 45: 1599 (Abstract E-1413).
11. Sutherland LR, Martin F, Greer S, et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis and proctitis. Gastroenterology 1987; 92: 1894-8.
12. Tran CP, Cook GA, Yeomans ND, et al. Trefoil peptide TFF2 (spasmolytic polypeptide) potently accelerates healing and reduces inflammation in a rat model of colitis. Gut 1999; 44: 636-42.
13. Babyatsky MW, de Beaumont M, Thim L, et al. Oral trefoil peptides protect against ethanol and indomethacin induced gastric injury in rats. Gastroenterology 1996; 110: 489-97.
14. Baron JH, Connell AM, Lennard-Jones JE. Variation between observers in describing mucosal appearances in proctocolitis. BMJ 1964; 1: 89-92.
15. Powell-Tuck J, Day DW, Buckell NA, et al. Correlation between defined sigmoidoscopic appearances and other measures of disease activity in ulcerative colitis. Dig Dis Sci 1982; 27: 533-7.
16. Playford RJ, Marchbank T, Chinery R, et al. Human spasmolytic polypeptide is a cytoprotective agent that stimulates cell migration. Gastroenterology 1995; 108: 108-16.
17. Cook GA, Thim L, Yeoman ND, et al. Oral human spasmolytic polypeptide protects against aspirin induced gastric injury in rats. J Gastroenterol Hepatol 1998; 13: 363-70.
18. Chinery R, Playford RJ. Combined intestinal trefoil factor and epidermal growth factor is prophylactic against indomethacin-induced gastric damage in the rat. Clin Sci (Lond) 1995; 88: 401-3.
19. Farrell JJ, Taupin D, Koh TJ, et al. TFF2/SP deficient mice show decreased gastric proliferation, increased acid secretion and increased susceptibility to NSAID injury. J Clin Invest 2002; 109: 193-204.
20. Lefebvre O, Chenard MP, Masson R, et al. Gastric mucosa abnormalities and tumorigenesis in mice lacking the pS2 trefoil protein. Science 1996; 274: 259-62.
21. Thim L, Madsen F, Polusen SS. Effect of trefoil factors on the viscoelastic properties of mucus gels. Eur J Clin Invest 2002; 32: 519-27.
22. Taupin DR, Kinoshita K, Podolsky DK. Intestinal trefoil factor confers colonic epithelial resistance to apoptosis. Proc Natl Acad Sci U S A 2000; 97: 799-804.
23. Liu D, el-Hariry I, Karayiannakis AJ, et al. Phosphorylation of beta-catenin and epidermal growth factor receptor by intestinal trefoil factor. Lab Invest 1997; 77: 557-63.
24. Sinha A, Nightingale JMD, West KP, et al. Epidermal growth factor enemas with oral mesalamine for mild to moderate left sided ulcerative colitis or proctitis. NEJM 2003; 349: 350-7.
25. Semple JI, Newton JL, Westley BR, et al. Dramatic diurnal variation in the concentration of the human trefoil peptide TFF2 in gastric juice. Gut 2001; 48: 648-55.
26. Meyers S, Janowitz, HD. The 'natural history' of ulcerative colitis: an analysis of the placebo response. J Clin Gastroenterol 1989; 11: 33-7.
27. Klotz U. The role of aminosalicylates at the beginning of the new millennium in the treatment of chronic inflammatory bowel disease. Eur J Clin Pharmacol 2000; 56: 353-62.
28. Sutherland LR, May GR, Shaffer EA. Sulfasalazine revisited: a meta analysis of 5-amino salicylic acid in the treatment of ulcerative colitis. Ann Intern Med 1993; 118: 540-9.
29. Safdi M, DeMicco M, Sninsky C, et al. A double blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol 1997; 92: 1867-71.
30. Sandborn WJ, Sands BE, Wolf DC, et al. Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized double-blind placebo controlled dose escalation trial. Aliment Pharmacol Ther 2003; 17: 1355-64.
31. Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn's disease: a randomized double blind placebo controlled trial. Gastroenterology 2001; 121: 1088-94.
32. Poulsen SS, Thulesen J, Christensen L, et al. Metabolism of oral trefoil factor 2 (TFF2) and the effect of oral and parenteral TFF2 on gastric and duodenal ulcer healing in the rat. Gut 1999; 45: 516-22.
33. Vandenbroucke K, Hans W, Van Huysse J, et al. Active delivery of trefoil factors by genetically modified Lactococcus lactis prevents and heals acute colitis in mice. Gastroenterology 2004; 127: 502-13.
34. Fitzgerald AJ, Pu M, Marchbank T, et al. Synergistic effects of systemic trefoil factor family 1 (TFF1) peptide and epidermal growth factor in a rat model of colitis. Peptides 2004; 25: 793-801.